Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1436
Gene Symbol: CSF1R
CSF1R
0.400 GeneticVariation group CLINVAR FMS mutations in myelodysplastic, leukemic, and normal subjects. 2406720 1990
Entrez Id: 613
Gene Symbol: BCR
BCR
0.100 GeneticVariation group BEFREE We surveyed DNAs from patients with various hematological malignancies by Southern blot hybridization to analyze bcr rearrangements, and detected a new restriction fragment length polymorphism (RFLP) of the breakpoint cluster region at a BamHI site in three patients. 2902258 1988
Entrez Id: 2539
Gene Symbol: G6PD
G6PD
0.030 Biomarker group BEFREE We have evaluated the hypothesis of a negative association between glucose 6-phosphate dehydrogenase (G6PD) deficiency and cancer in a cohort of 481 Sardinian males with hematological malignancies. 3348216 1988
Entrez Id: 5744
Gene Symbol: PTHLH
PTHLH
0.010 Biomarker group BEFREE Recently developed radioimmunoassays and tissue localization techniques indicate that PTHrP is produced by many more cancers than was originally indicated by clinical studies and that it contributes significantly to malignancy-related hypercalcemia associated with other etiologies, for example, cancers metastatic to bone and hematological malignancies. 7495499 1995
Entrez Id: 595
Gene Symbol: CCND1
CCND1
0.040 AlteredExpression group BEFREE Immunohistochemical expression of PRAD1/cyclin D1 protein has been investigated in 106 tissue specimens of 104 cases of lymphoma, non-neoplastic lymphoid disorders and other hematologic malignancies by employing the monoclonal antibody 5D4 with formalin-fixed paraffin-embedded sections, using the microwave oven heating method. 7531681 1994
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker group BEFREE To determine if CDKN2 or another closely related gene on 9p is the target of 9p deletions in ALL and other hematologic malignancies, we analyzed 20 primary patient samples (13 ALL, 2 acute myeloid leukemias [AML], and 5 non-Hodgkin's lymphomas [NHL]) with 9p rearrangements using Southern blot analysis, fluorescence in situ hybridization (FISH), and single-strand conformation polymorphism (SSCP) for alterations of CDKN2. 7544647 1995
Entrez Id: 1017
Gene Symbol: CDK2
CDK2
0.020 Biomarker group BEFREE To determine if CDKN2 or another closely related gene on 9p is the target of 9p deletions in ALL and other hematologic malignancies, we analyzed 20 primary patient samples (13 ALL, 2 acute myeloid leukemias [AML], and 5 non-Hodgkin's lymphomas [NHL]) with 9p rearrangements using Southern blot analysis, fluorescence in situ hybridization (FISH), and single-strand conformation polymorphism (SSCP) for alterations of CDKN2. 7544647 1995
Entrez Id: 7586
Gene Symbol: ZKSCAN1
ZKSCAN1
0.010 GeneticVariation group BEFREE In addition, several of the ZNFs mapped to regions implicated in recurrent chromosomal rearrangements in hematological malignancies (ZNF139, 7q21.3-q22.1; ZNF148, 3q21-q22; ZNF151, 1p36.1-p36.2). 7557990 1995
Entrez Id: 5243
Gene Symbol: ABCB1
ABCB1
0.400 GeneticVariation group BEFREE Prospective phase I, II, and III clinical trials using reversing agents in conjunction with chemotherapy in malignancies that express the MDR1 gene, such as the hematologic malignancies and breast cancer, are necessary before routine use of agents such as verapamil, quinidine, and cyclosporine, which carry innate toxicities. 7600845 1995
Entrez Id: 23158
Gene Symbol: TBC1D9
TBC1D9
0.100 GeneticVariation group BEFREE Prospective phase I, II, and III clinical trials using reversing agents in conjunction with chemotherapy in malignancies that express the MDR1 gene, such as the hematologic malignancies and breast cancer, are necessary before routine use of agents such as verapamil, quinidine, and cyclosporine, which carry innate toxicities. 7600845 1995
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation group BEFREE Our data provide further evidence that among hematological malignancies, ALL are the most likely to be associated with p16INK4A inactivation, mainly by homozygous gene deletion. 7630199 1995
Entrez Id: 5243
Gene Symbol: ABCB1
ABCB1
0.400 AlteredExpression group BEFREE The standardization of methods for P-gp, permitting large multicentric studies, and the results of randomized studies with modifier agents will help us know if mdr1 gene overexpression is of clinical importance in hematologic malignancies. 7642463 1995
Entrez Id: 23158
Gene Symbol: TBC1D9
TBC1D9
0.100 AlteredExpression group BEFREE The standardization of methods for P-gp, permitting large multicentric studies, and the results of randomized studies with modifier agents will help us know if mdr1 gene overexpression is of clinical importance in hematologic malignancies. 7642463 1995
Entrez Id: 3429
Gene Symbol: IFI27
IFI27
0.010 GeneticVariation group BEFREE These results indicate that p27 gene alterations are rare events in NHLs and ATLs, but may play an important role in the pathogenesis of some hematologic malignancies. 7655021 1995
Entrez Id: 353376
Gene Symbol: TICAM2
TICAM2
0.010 GeneticVariation group BEFREE These results indicate that p27 gene alterations are rare events in NHLs and ATLs, but may play an important role in the pathogenesis of some hematologic malignancies. 7655021 1995
Entrez Id: 51014
Gene Symbol: TMED7
TMED7
0.010 GeneticVariation group BEFREE These results indicate that p27 gene alterations are rare events in NHLs and ATLs, but may play an important role in the pathogenesis of some hematologic malignancies. 7655021 1995
Entrez Id: 10534
Gene Symbol: ZNRD2
ZNRD2
0.010 GeneticVariation group BEFREE These results indicate that p27 gene alterations are rare events in NHLs and ATLs, but may play an important role in the pathogenesis of some hematologic malignancies. 7655021 1995
Entrez Id: 115482696
Gene Symbol: H3P23
H3P23
0.010 GeneticVariation group BEFREE These results indicate that p27 gene alterations are rare events in NHLs and ATLs, but may play an important role in the pathogenesis of some hematologic malignancies. 7655021 1995
Entrez Id: 5715
Gene Symbol: PSMD9
PSMD9
0.010 GeneticVariation group BEFREE These results indicate that p27 gene alterations are rare events in NHLs and ATLs, but may play an important role in the pathogenesis of some hematologic malignancies. 7655021 1995
Entrez Id: 100302736
Gene Symbol: TMED7-TICAM2
TMED7-TICAM2
0.010 GeneticVariation group BEFREE These results indicate that p27 gene alterations are rare events in NHLs and ATLs, but may play an important role in the pathogenesis of some hematologic malignancies. 7655021 1995
Entrez Id: 10671
Gene Symbol: DCTN6
DCTN6
0.010 GeneticVariation group BEFREE These results indicate that p27 gene alterations are rare events in NHLs and ATLs, but may play an important role in the pathogenesis of some hematologic malignancies. 7655021 1995
Entrez Id: 7974
Gene Symbol: HRX
HRX
0.010 Biomarker group BEFREE The HRX gene has recently been shown to be involved in most of the chromosomal abnormalities of band 11q23 frequently present in human hematological malignancies. 7658717 1995
Entrez Id: 4437
Gene Symbol: MSH3
MSH3
0.010 GeneticVariation group BEFREE These results suggest that inactivation of the hMSH3 gene may be involved in the development of hematological malignancies. 7669036 1995
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation group BEFREE Mutations of p53 frequently occur in a wide variety of cancers including lung, breast, gastrointestinal, brain, and hematologic malignancies. 7675765 1995
Entrez Id: 1630
Gene Symbol: DCC
DCC
0.030 GeneticVariation group BEFREE Expression of the DCC gene in human hematological malignancies. 7696919 1994